Skip to main content
. Author manuscript; available in PMC: 2017 Feb 1.
Published in final edited form as: Biomaterials. 2015 Dec 2;79:56–68. doi: 10.1016/j.biomaterials.2015.11.056

Figure 4.

Figure 4

(a) TEM images of DOTAP-based MNCPs without (left) or with (right) negative staining. Adapted from [28]. (b) The in vivo silencing effect of luciferase siRNA delivered by DOTAP-based and DOPC-based MNCPs at different doses. Adapted from [28].